Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.
Shattuck Labs, Inc. files a preliminary prospectus supplement to offer shares of common stock and pre-funded warrants in a registered shelf offering, and disclosed recent clinical and financing developments.
The company announced Phase 1 data for lead antibody candidate SL-325 on June 8, 2026, reported notices to exercise approximately $54.9 million of common stock warrants (approximately 50.6M warrants), and stated existing cash, cash equivalents and short-term investments of $90.4 million as of March 31, 2026, with an expected funding runway into 2029 assuming full exercise of remaining warrants.
Shattuck Labs reported encouraging Phase 1 results for SL-325, its lead DR3 blocking antibody, and a major cash influx from warrant exercises. The first-in-human trial in 72 healthy volunteers showed SL-325 was well tolerated across single and multiple ascending doses, with durable DR3 receptor occupancy, no evidence of agonist activity, and a low anti-drug antibody rate of 3.7%.
The company plans to start the RECEPTIVE-CD1 randomized Phase 2b trial of SL-325 in moderate-to-severe Crohn’s disease in the third quarter of 2026 and target 12-week induction data in the first half of 2028. Shattuck also highlighted SL-846, a DR3 x IL-23R bispecific antibody now in IND-enabling toxicology studies, with Phase 1 initiation expected in the first half of 2027.
Financially, Shattuck has received or expects to receive aggregate gross proceeds of approximately $54.9 million from the exercise of about 50.6 million common stock warrants, representing roughly 96% of warrants issued in an August 4, 2025 private placement. Combined with approximately $90.4 million in cash, cash equivalents and short-term investments as of March 31, 2026, the company now expects to fund operations into 2029 based on current plans.
Shattuck Labs, Inc. reported that director Daniel G. Baker received a grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on May 29, 2036.
The award vests in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, as long as Baker continues to serve the company. After this grant, he holds options on 81,000 shares directly.
Shattuck Labs, Inc. director George Golumbeski received a compensation-related grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on May 29, 2036. They vest in full on the earlier of the one-year anniversary of the May 29, 2026 grant date or immediately before the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, he holds 81,000 stock options directly.
Shattuck Labs, Inc. director Neil W. Gibson received a grant of stock options covering 81,000 shares of common stock. These options have an exercise price of $5.95 per share and expire on May 29, 2036.
The option grant vests in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, as long as Gibson continues to serve the company. Following this grant, he holds options for 81,000 shares directly.
Shattuck Labs director Ashiya Mona received a grant of stock options covering 81,000 shares of common stock. These options have an exercise price of $5.95 per share and expire on May 29, 2036. They vest in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual stockholder meeting, contingent on continued service.
Under an agreement with OrbiMed entities, any securities or economic benefits from these options must be transferred so they ultimately accrue to OrbiMed Private Investments IX, LP. This is a compensation-related award, not an open-market purchase or sale.
Shattuck Labs, Inc. director Clay B. Siegall received a grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and expire on May 29, 2036. They vest in full on the earlier of the one-year anniversary of the grant date or immediately before the company’s next annual stockholder meeting, as long as he continues serving the company. This is a compensation-related award, not an open-market purchase or sale, and results in 81,000 derivative securities held after the transaction.
Shattuck Labs director Helen M. Boudreau received a grant of stock options covering 81,000 shares of common stock. The options have an exercise price of $5.95 per share and give her the right to buy the shares in the future.
According to the terms, the 81,000 options will vest in full on the earlier of the one-year anniversary of the May 29, 2026 grant date or immediately before Shattuck Labs’ next annual meeting of stockholders, subject to her continued service. Following this grant, she holds 81,000 derivative securities directly.
Shattuck Labs, Inc. reported results from its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment and restatement of the 2020 Equity Incentive Plan to increase the shares available for issuance by 1,691,082 and extend the plan’s term to March 23, 2036.
As of the April 2, 2026 record date, 75,581,787 shares of common stock were entitled to vote. All three Class III director nominees were elected, KPMG LLP was ratified as independent auditor, and the advisory vote on executive compensation passed. Stockholders favored holding future say‑on‑pay votes every year, and the company plans to conduct these votes annually.
Shattuck Labs director Clay B. Siegall increased his direct stake by exercising warrants for common stock. On May 22, 2026, he acquired 128,054 shares of common stock at an exercise price of $1.0846 per share through the exercise of warrants.
These warrants were originally issued in a private placement under an August 4, 2025 securities purchase agreement, where he bought 128,054 shares of common stock with accompanying warrants at a combined price of $0.8677 per share and warrant. Following the latest transactions, Siegall directly holds 256,108 common shares, with the exercised warrants position reduced to zero.